Atossa Genetics Stock EBITDA
| ATOS Stock | USD 0.79 0.02 2.60% |
Fundamental analysis of Atossa Genetics allows traders to better anticipate movements in Atossa Genetics' stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| EBITDA | -25.5 M | -24.2 M |
Atossa | EBITDA | Build AI portfolio with Atossa Stock |
Atossa Genetics Company EBITDA Analysis
Atossa Genetics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Atossa Genetics EBITDA | (25.49 M) |
Most of Atossa Genetics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Atossa Genetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Atossa EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Atossa Genetics is extremely important. It helps to project a fair market value of Atossa Stock properly, considering its historical fundamentals such as EBITDA. Since Atossa Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Atossa Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Atossa Genetics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Atossa Ebitda
Ebitda |
|
According to the company disclosure, Atossa Genetics reported earnings before interest,tax, depreciation and amortization of (25.49 Million). This is 102.9% lower than that of the Health Care Equipment & Supplies sector and 125.45% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.65% higher than that of the company.
Atossa EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atossa Genetics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atossa Genetics could also be used in its relative valuation, which is a method of valuing Atossa Genetics by comparing valuation metrics of similar companies.Atossa Genetics is currently under evaluation in ebitda category among its peers.
Atossa Genetics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Atossa Genetics from analyzing Atossa Genetics' financial statements. These drivers represent accounts that assess Atossa Genetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Atossa Genetics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 4.2M | 13.3M | 10.7M | 118.8M | 106.9M | 112.3M | |
| Enterprise Value | (6.1M) | 809.6K | (28.8M) | 47.7M | 54.9M | 57.6M |
Atossa Genetics Institutional Holders
Institutional Holdings refers to the ownership stake in Atossa Genetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Atossa Genetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Atossa Genetics' value.| Shares | Bank Of New York Mellon Corp | 2025-03-31 | 289.7 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 284.2 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-03-31 | 189.3 K | Goldman Sachs Group Inc | 2025-03-31 | 187.9 K | Nuveen, Llc | 2025-03-31 | 170.7 K | Rhumbline Advisers | 2025-03-31 | 129.9 K | Barclays Plc | 2025-03-31 | 128.6 K | Jpmorgan Chase & Co | 2025-03-31 | 118.9 K | Qube Research & Technologies | 2025-03-31 | 91 K | Blackrock Inc | 2025-03-31 | 9.6 M | Vanguard Group Inc | 2025-03-31 | 6.6 M |
Atossa Fundamentals
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 43.66 M | ||||
| Shares Outstanding | 129.17 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 20.41 % | ||||
| Number Of Shares Shorted | 3.81 M | ||||
| Price To Earning | (0.62) X | ||||
| Price To Book | 1.73 X | ||||
| EBITDA | (25.49 M) | ||||
| Net Income | (25.5 M) | ||||
| Cash And Equivalents | 125.54 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 4.97 M | ||||
| Current Ratio | 35.19 X | ||||
| Book Value Per Share | 0.45 X | ||||
| Cash Flow From Operations | (21.03 M) | ||||
| Short Ratio | 3.01 X | ||||
| Earnings Per Share | (0.22) X | ||||
| Target Price | 5.63 | ||||
| Number Of Employees | 15 | ||||
| Beta | 0.92 | ||||
| Market Capitalization | 101.51 M | ||||
| Total Asset | 76.44 M | ||||
| Retained Earnings | (211.79 M) | ||||
| Working Capital | 69.49 M | ||||
| Current Asset | 4.29 M | ||||
| Current Liabilities | 2.5 M | ||||
| Net Asset | 76.44 M |
About Atossa Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atossa Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atossa Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atossa Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.